GLOBAL MARKET FOR ANTIFUNGAL THERAPEUTICS TO REACH $12.2 BILLION IN 2016 Wellesley, Mass.

According to a new technical market research report, ANTIFUNGAL DRUGS: TECHNOLOGIES AND GLOBAL MARKETS (PHM029D) from BCC Research (www.bccresearch.com), the global market for antifungal therapeutics was valued at $10.7 billion in 2011 and is projected to reach $12.2 billion in 2016, a five-year compound annual growth rate (CAGR) of 2.7%. The antifungal drug market can be separated into four regions: the U.S., Europe, Japan, and the rest of the world. The U.S. accounted for nearly $4.5 billion in 2011 and is projected to total nearly $4.9 billion in 2016, a CAGR of 1.7%. Europe totaled $3.6 billion in 2011 and is projected to be worth $3.9 billion in 2016, a CAGR of 1.5%. Japan, worth $963 million in 2011, is expected to be worth $1.2 billion in 2016, a CAGR of 5.3%. The rest of the world accounted for $1.6 billion in 2011 and is projected to total nearly $2.2 billion in 2016, making it the segment with the highest CAGR over the five-year period, 6.3%. Fungi are highly resistant microbiological eukaryotic microorganisms; in other words, they are becoming drug-resistant to the approved compounds and some therapies later in clinical development. The therapies are designed to eradicate them through the various antifungal mechanisms of action, such as disrupting reproductive capabilities, destroying cell walls, or modifying fungal DNA and cell functioning. It is a fact that infestations in humans, animals, plants, and the environment are on the rise, with many having lethal consequences in both the immunocompetent and the immunocompromised. This report will help its audience:

Determine the current status of the global human antifungal market Assess the markets growth potential over the five-year period from 2011 to 2016 Analyze data regarding the market shift for those products that are now relegated to overthe-counter (OTC) status, previously having only been provided with a prescription Identify new antifungal research, development, new drug applications, and novel approaches to the market

Cover new drug and patent applications, which are presented as the study focuses on new methods of drug administration, drug clinical trials, and discovery and development

This study will be of significant interest to hospitals, pharmacies, pharmaceutical companies, biopharmaceutical researchers, pharmaceutical company marketing executives, contract research organizations (CROs), chemists, physicians, nurses, physician assistants, pharmaceutical directors, product managers and representatives, all manner of institutional directors ranging from nursing homes and schools to long-term-care facilities both public and private. It also will be of interest to biologists and those interested in the field of mycology. SUMMARY FIGURE GLOBAL SALES OF HUMAN ANTIFUNGALS, 2011 AND 2016 ($ MILLIONS)

Source: BCC Research Data and analysis extracted from this press release must be accompanied by a statement identifying BCC Research LLC, 49 Walnut Park, Building 2, Wellesley, MA 02481, Telephone: 866-285-7215; Email: editor@bccresearch.com as the source and publisher, along with report number, which can be found in the first paragraph of this release. Thank you.